niacinamide has been researched along with Kidney Diseases in 20 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight-week-old rats were subjected to unilateral ureteral obstruction (UUO) and were intragastrically administered sorafenib, while control and sham groups were administered vehicle for 14 or 21 days." | 7.81 | Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. ( Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L, 2015) |
| "Eight-week-old rats were subjected to unilateral ureteral obstruction (UUO) and were intragastrically administered sorafenib, while control and sham groups were administered vehicle for 14 or 21 days." | 3.81 | Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. ( Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L, 2015) |
| "Recently, cancer therapies have been supplemented by vascular endothelial growth factor (VEGF) inhibitors as anti-angiogenic agents." | 2.50 | Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. ( Chandran, CB; Flombaum, CD; Glezerman, IG; Salvatore, SP; Seshan, SV; Usui, J, 2014) |
| " With expanded clinical experience with this class of agents has come the increasing recognition of the diverse adverse effects related to disturbance of VEGF-dependent physiological functions and homeostasis in the cardiovascular and renal systems, as well as wound healing and tissue repair." | 2.45 | Adverse effects of anticancer agents that target the VEGF pathway. ( Chen, HX; Cleck, JN, 2009) |
| "Renal interstitial fibrosis is a common pathological feature in progressive kidney diseases currently lacking effective treatment." | 1.51 | Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation. ( Cai, J; Dong, Z; Liu, Z; Shu, S; Tang, C; Wang, Y; Zheng, M, 2019) |
| " Dose recommendations for these patients are not available because pharmacokinetic data are missing." | 1.37 | Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients. ( Bode-Böger, SM; Luley, C; Martens-Lobenhoffer, J; Reiche, I; Tröger, U; Westphal, S, 2011) |
| " No significant difference was noted in any of the other pharmacokinetic parameters examined in the three groups, not even on comparing values obtained on the first and last days of treatment." | 1.28 | Pharmacokinetics of nicorandil in patients with normal and impaired renal function. ( Molinaro, M; Regazzi, MB; Rondanelli, R; Salvadeo, A; Sartirana, E; Segagni, S; Villa, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, M | 1 |
| Cai, J | 1 |
| Liu, Z | 1 |
| Shu, S | 1 |
| Wang, Y | 1 |
| Tang, C | 1 |
| Dong, Z | 1 |
| Izzedine, H | 1 |
| Mangier, M | 1 |
| Ory, V | 1 |
| Zhang, SY | 1 |
| Sendeyo, K | 1 |
| Bouachi, K | 1 |
| Audard, V | 1 |
| Péchoux, C | 1 |
| Soria, JC | 1 |
| Massard, C | 1 |
| Bahleda, R | 1 |
| Bourry, E | 1 |
| Khayat, D | 1 |
| Baumelou, A | 1 |
| Lang, P | 1 |
| Ollero, M | 1 |
| Pawlak, A | 1 |
| Sahali, D | 1 |
| Usui, J | 1 |
| Glezerman, IG | 1 |
| Salvatore, SP | 1 |
| Chandran, CB | 1 |
| Flombaum, CD | 1 |
| Seshan, SV | 1 |
| Jia, L | 1 |
| Ma, X | 1 |
| Gui, B | 1 |
| Ge, H | 1 |
| Wang, L | 1 |
| Ou, Y | 1 |
| Tian, L | 1 |
| Chen, Z | 1 |
| Duan, Z | 1 |
| Han, J | 1 |
| Fu, R | 1 |
| Nouhaud, FX | 1 |
| Pfister, C | 1 |
| Defortescu, G | 1 |
| Giwerc, A | 1 |
| Charbit, D | 1 |
| Gouerant, S | 1 |
| Sabourin, JC | 1 |
| Di Fiore, F | 1 |
| Hsieh, JJ | 1 |
| Purdue, MP | 1 |
| Signoretti, S | 1 |
| Swanton, C | 1 |
| Albiges, L | 1 |
| Schmidinger, M | 1 |
| Heng, DY | 1 |
| Larkin, J | 1 |
| Ficarra, V | 1 |
| MESSINA, R | 1 |
| Hilger, RA | 1 |
| Richly, H | 1 |
| Grubert, M | 1 |
| Kredtke, S | 1 |
| Thyssen, D | 1 |
| Eberhardt, W | 1 |
| Hense, J | 1 |
| Schuler, M | 1 |
| Scheulen, ME | 1 |
| Chen, HX | 1 |
| Cleck, JN | 1 |
| Reiche, I | 1 |
| Westphal, S | 1 |
| Martens-Lobenhoffer, J | 1 |
| Tröger, U | 1 |
| Luley, C | 1 |
| Bode-Böger, SM | 1 |
| Karpishchenko, SN | 1 |
| Zheregelia, SN | 1 |
| Glushkov, SI | 1 |
| Cheng, SC | 1 |
| Young, DO | 1 |
| Huang, Y | 1 |
| Delmez, JA | 1 |
| Coyne, DW | 1 |
| McDonald, MC | 1 |
| Filipe, HM | 1 |
| Thiemermann, C | 1 |
| Stroo, WE | 1 |
| Hook, JB | 1 |
| Chow, AY | 1 |
| Hirsch, GH | 1 |
| Buttar, HS | 1 |
| Wold, JS | 1 |
| Turnipseed, SA | 1 |
| Miller, BL | 1 |
| Lock, EA | 1 |
| Ishmael, J | 1 |
| Maïza, A | 1 |
| Waldek, S | 1 |
| Ballardie, FW | 1 |
| Daley-Yates, PT | 1 |
| Molinaro, M | 1 |
| Villa, G | 1 |
| Regazzi, MB | 1 |
| Salvadeo, A | 1 |
| Segagni, S | 1 |
| Rondanelli, R | 1 |
| Sartirana, E | 1 |
| Somogyi, A | 1 |
| Siebert, D | 1 |
| Bochner, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients[NCT00316472] | Phase 1 | 40 participants | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niacinamide and Kidney Diseases
| Article | Year |
|---|---|
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplasti | 2014 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney | 2017 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
1 trial available for niacinamide and Kidney Diseases
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
Topics: Administration, Oral; Biomarkers; Chelating Agents; Cross-Over Studies; Double-Blind Method; Down-Re | 2008 |
16 other studies available for niacinamide and Kidney Diseases
| Article | Year |
|---|---|
Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation.
Topics: Animals; Apoptosis; Cell Line; Chemokine CCL2; Disease Models, Animal; Fibrosis; Inflammation; Inter | 2019 |
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; | 2014 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Tra | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2015 |
The influence of vitamin PP on the exchange of creatine and creatinine in some morbid conditions; behavior of creatine and nephrópatients
Topics: Creatine; Kidney Diseases; Niacinamide; Nutrition Therapy | 1948 |
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Blood Specimen Collection; Clinical Trials as Topic; Dose- | 2009 |
Pharmacokinetics and dose recommendations of Niaspan® in chronic kidney disease and dialysis patients.
Topics: Aged; Chronic Disease; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2011 |
[Using cytoflavin for correcting x-ray contrasting agent-induced nephropathy].
Topics: Animals; Contrast Media; Cytoprotection; Drug Combinations; Flavin Mononucleotide; Inosine Diphospha | 2010 |
Effects of inhibitors of the activity of poly (ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzamides; Blood Pressure; Creatine Kin | 1999 |
Enzymes of renal origin in urine as indicators of nephrotoxicity.
Topics: Alkaline Phosphatase; Animals; Blood Urea Nitrogen; Carbon Tetrachloride; Folic Acid; Glucosidases; | 1977 |
Nephrotoxic and hepatotoxic effects of triclosan and chlorhexidine in rats.
Topics: Age Factors; Animals; Biguanides; Chemical and Drug Induced Liver Injury; Chlorhexidine; Female; Kid | 1977 |
The effect of renal cation transport inhibition on cephaloridine nephrotoxicity.
Topics: Animals; Biological Transport; Blood Urea Nitrogen; Cations; Cephaloridine; Cyanides; Drug Interacti | 1979 |
The acute toxic effects of paraquat and diquat on the rat kidney.
Topics: Animals; Carbon Dioxide; Diquat; Fatty Acids; Glucose; Kidney Diseases; Male; Mercury; Niacinamide; | 1979 |
Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Creatine; Female; Glomerular Filtration Rate; Humans; Ki | 1992 |
Pharmacokinetics of nicorandil in patients with normal and impaired renal function.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Female; Half-Life; Humans; Kidney Diseas | 1992 |
Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by high-performance liquid chromatography.
Topics: Acetophenones; Adolescent; Adult; Aged; Aging; Chromatography, High Pressure Liquid; Female; Fluores | 1990 |